Last week, we announced that Oak is investing in Akido Labs’ Series B to help the company further its mission of reshaping how healthcare is delivered through the use of AI. Today, Akido is providing care for more than 500,000 patients across California, Rhode Island, and New York. With the Oak investment, the team is positioning itself to scale even further, primarily through the use of ScopeAI, Akido’s groundbreaking clinical AI system that will help address the growing physician shortage and demand-supply imbalance that we are seeing today in the U.S. healthcare system.
The U.S. healthcare system is currently facing a staggering physician shortfall: to properly meet patient needs, more than 3 billion doctor visits are required each year, yet only 825 million are currently available, based on current clinical capacity. This gap has led to longer wait times – especially for specialists – shorter appointments, and a rise in preventable disease.
Akido is tackling this problem head on by rethinking how AI can expand access to care – particularly for underserved populations. Founded in 2015, Akido uses a dual-platform strategy: the company 1) delivers care via its medical network of 240+ providers across 26 specialities, and 2) augments its clinical team with ScopeAI, the company’s proprietary system that is designed to expand the reach of specialists by 3-4x in fields like cardiology, endocrinology, pulmonology, and street medicine.
Unlike simple patient intake forms or note-taking assistants, ScopeAI offers robust tooling and expertise so that a trained Medical Assistant (MA) can manage visits with less complex patients, ultimately allowing physicians to oversee many more patient encounters and focus more time on complex cases. By guiding the MA through the visit, ScopeAI listens, adapts, and generates clinical reports, including recommended treatment plans. Physicians review and sign off on treatment plans to ensure that care remains human-centric. And, patients are loving the experience, with the product receiving a 96 NPS score and delivering ~5x more face-to-face time during patient visits.
ScopeAI was originally trained on a foundational dataset of over 10 million real-world patient cases, spanning a wide range of outpatient specialties. Today, it continues to evolve through a reinforcement learning loop informed by feedback from over 240 practicing clinicians. This approach has resulted in a platform that not only expands clinical capacity, but also understands how medicine is practiced at a local level. Importantly, it also provides a robust justification log for every decision made – increasing physician confidence in the tool.
Akido’s business model and growth trajectory reflect a rare combination of scale, innovation, and market fit. With an increase in its patient base by 100% YoY, the company is demonstrating both strong near-term performance and long-term potential. Oak HC/FT’s investment is grounded in Akido’s compelling market positioning, its AI-driven scalability, and the opportunity for hypergrowth as ScopeAI reshapes clinical delivery. Akido is also rapidly expanding its geographic footprint, including a first-of-its-kind care program in New York City focused on chronic disease management for rideshare and for-hire drivers, with additional market launches on the horizon.
We were initially drawn to Akido because of their unique combination of clinical and technical expertise, its robust dataset, and its potential to redefine healthcare delivery. And, importantly, we think their leadership team is exceptional. Prashant, Jared, and Sanjit have a unique combination of technical prowess, operational focus, and a hunger to change the healthcare system for those that need it most. Their approach to expansion and growth is thoughtful and ambitious, but focused on expanding access, not just margins. The trio is intensely mission-driven, with their connection to the communities they are serving extending beyond the care Akido is providing. This passion for their mission is a true talent magnet, and we are confident it will help them stay focused as they build a scaled business.
AI is poised to fundamentally transform care delivery, and Akido is at the forefront of that shift. By pairing medical assistants with real-time clinical AI guidance, ScopeAI creates a scalable care model that expands provider reach, reduces burnout, and improves access – directly addressing the growing physician shortage. Rather than replacing doctors, ScopeAI augments them with clinical accuracy and adaptive intelligence, enabling more precise, personalized care delivered with greater empathy. This aligns with the increasingly prevailing view that AI will redefine how medicine is practiced – from diagnosis and triage to treatment planning and patient engagement – unlocking new levels of efficiency and human connection. As the technology evolves, Akido isn’t just responding to the future of healthcare – it’s actively building it. We are honored to be on this journey with them.